CClinicalTrials.gg
Enrolling by invitationNCT06837038Updated Feb 20, 2025

Clinical Study of Rhythmic Auditory Stimulation for Gait Disorders

An interventional study of rhythmic auditory stimulation and No rhythm stimulation in Hemiplegia Due to Stroke, Parkinson Disease and Parkinsonian Syndrome, sponsored by YiCheng Zhu. Enrolling by invitation at 1 site in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by YiCheng Zhu · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 11 months ago, but the record still lists the study as enrolling by invitation.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Study summary

The aim of this clinical trial was to determine whether rhythmic auditory stimulation is effective in treating gait disorders in patients with post-stroke hemiplegia, primary Parkinson's disease, and various parkinsonism syndromes. The main questions it aims to answer are:

Does rhythmic auditory stimulation increase walking speed in patients with gait disorders? To determine whether rhythmic auditory stimulation is effective in treating gait disorders, researchers will compare a gait rhythmometer with an active control that does not receive rhythmic stimulation.

Participants will:

Gait training was conducted once a day for 15 minutes for 7 consecutive days Resting-state functional magnetic resonance imaging (fmri) was performed before and after treatment Feedback on subjective improvement at the end of the 7-day treatment

02

Conditions studied

  • Hemiplegia Due to Stroke
  • Parkinson Disease
  • Parkinsonian Syndrome

Keywords

  • Rhythmic auditory stimulation
  • Hemiplegia after stroke
  • Parkinsonism syndrome
  • Gait disorders
  • Parkinson disease
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's planned enrollment of 60 is above the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

This is the only study on the registry with YiCheng Zhu as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

For post-stroke hemiplegia

Inclusion criteria :

  • Age 50-80 years old
  • One or more strokes (cerebral infarction or cerebral hemorrhage), with the most recent stroke occurring at least 6 months earlier
  • Walking independently without a cane or walking aid with obvious gait asymmetry
  • 0.4m/s\< baseline velocity \<0.8m/s
  • Sufficient hearing, vision and comprehension to complete motor function tests
  • Patients were willing and able to participate in all study procedures and signed informed consent
  • No other rehabilitation treatment was received at present

Exclusion Criteria:

  • Unable to cooperate with the motor function test
  • Uncontrolled hypertension
  • Myocardial infarction within the past 3 months
  • With bone and joint diseases, such as a history of lower limb fracture within 1 year, waist and lower limb bone and joint surgery, bone and joint deformity seriously affecting walking, etc.
  • Except for stroke, there was no parkinsonism, myasthenia gravis, poliomyelitis and other nervous system diseases affecting the walking function of patients.

For primary Parkinson's disease (PD)

Inclusion criteria:

  • Age 50-80 years old
  • PD met the diagnostic criteria of Chinese Diagnostic Criteria for Parkinson's Disease (2016 edition)
  • Obvious panic gait, freezing gait or slow gait, but can walk independently without the use of a cane or walking aid
  • Hoehn-Yahr (H-Y) stage 2-4
  • 0.4m/s\< baseline velocity \<0.8m/s
  • Sufficient hearing, vision and comprehension to complete motor function tests
  • Patients were willing and able to participate in all study procedures and signed informed consent
  • No other rehabilitation treatment was received at present

Exclusion criteria:

  • Unable to cooperate with the motor function test
  • Uncontrolled hypertension
  • Myocardial infarction within the past 3 months
  • With bone and joint diseases, such as a history of lower limb fracture within 1 year, waist and lower limb bone and joint surgery, bone and joint deformity seriously affecting walking, etc
  • There was no stroke, myasthenia gravis, poliomyelitis and other neurological diseases affecting the walking function except for primary Parkinson's disease

For Parkinsonism syndrome:

Inclusion criteria:

  • Age 50-80 years old
  • All parkinsonism syndrome except primary Parkinson's disease, including but not limited to drug-induced parkinsonism, multiple system atrophy, cerebral small vessel disease-related parkinsonism, etc
  • obvious panic gait, freezing gait or slow gait, but can walk independently without the use of a cane or walking aid
  • 0.4m/s\< baseline velocity \<0.8m/s
  • Sufficient hearing, vision and comprehension to complete motor function tests
  • Be willing and able to participate in all study procedures and sign informed consent
  • No other rehabilitation treatment was received at present.

Exclusion criteria:

  • Unable to cooperate with the motor function test
  • Uncontrolled hypertension
  • Myocardial infarction within the past 3 months
  • With bone and joint diseases, such as a history of lower limb fracture within 1 year, waist and lower limb bone and joint surgery, bone and joint deformity seriously affecting walking, etc
  • There was no stroke, myasthenia gravis, poliomyelitis and other neurological diseases that affected the walking function except for parkinsonism
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Rhythm intervention group

    Device: rhythmic auditory stimulation

  • Sham comparator
    Active control group

    Device: No rhythm stimulation

Interventions

  • Devicerhythmic auditory stimulation

    The intervention group was treated with a gait rhythm device under the supervision of the researchers. The complete gait training was conducted once a day for 15 minutes for 7 consecutive days. Each patient wore inertial sensors at both ankles during gait training to collect gait information during walking.

  • DeviceNo rhythm stimulation

    The control group received gait training without rhythmic auditory stimulation under the supervision of the researchers. The complete gait training was conducted once a day for 15 to 20 minutes for 7 consecutive days. Each patient wore inertial sensors at both ankles during gait training to collect gait information during walking.

06

What researchers measure

Primary outcomes

  1. Gait speed

    The difference between the gait speed measured on the third day after the completion of the seven gait sessions and the baseline gait speed

    Time frame: 10 days

Secondary outcomes

  1. Stride length

    The difference between the stride length (left and right) measured on the third day after the completion of the seven gait sessions and the baseline stride length.

    Time frame: 10 days

  2. Stride frequency

    The difference between the stride frequency (left and right) measured on the third day after the completion of the seven gait sessions and the baseline stride frequency.

    Time frame: 10 days

  3. Stride speed

    The difference between the stride speed (left and right) measured on the third day after the completion of the seven gait sessions and the baseline stride speed.

    Time frame: 10 days

  4. Swing speed

    The difference between the swing speed (left and right) measured on the third day after the completion of the seven gait sessions and the baseline swing speed.

    Time frame: 10 days

  5. Standing phase

    The difference between the standing phase (left and right) measured on the third day after the completion of the seven gait sessions and the baseline standing phase.

    Time frame: 10 days

  6. Turn time

    The difference between the turn time measured on the third day after the completion of the seven gait sessions and the baseline turn time.

    Time frame: 10 days

  7. Patient's SUBJECTIVE assessment

    All subjects were asked about their subjective feelings using a uniform questionnaire, including the following questions: Did the patient's gait problems improve after 7 days of treatment? If there has been improvement, in what ways? (Step speed, stride length, symmetry, turn time, etc.)

    Time frame: 10 days

  8. Resting-state functional magnetic resonance imaging

    At baseline and on the third day after completion of the 7-day gait treatment, 3T resting-state functional magnetic resonance imaging (rs-fMRI) was performed to compare the changes of local neural activity, including amplitude of low frequency fluctuation (ALFF) and functional connectivity density (FCD).

    Time frame: 10 days

07

Study locations

1 site
  • Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, Beijing 100730, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06837038
Lead sponsor
YiCheng Zhu
Responsible party
YiCheng Zhu (Project Leader, Peking Union Medical College Hospital) — Sponsor-investigator
First posted
Feb 20, 2025
Start date
Dec 1, 2024
Primary completion
Oct 31, 2025 (estimated)
Completion
Oct 31, 2025 (estimated)
Last update
Feb 20, 2025

Study contacts

Yicheng Zhu
study director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion